We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pfizer Considers Fablyn Next Step After Complete Response Letter
Pfizer Considers Fablyn Next Step After Complete Response Letter
January 23, 2009
The FDA has issued a complete response letter to Pfizer’s Fablyn NDA, which sought approval to treat osteoporosis in postmenopausal women who have an increased risk of bone fractures.